

# Jean-Pierre Pignon

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8161158/jean-pierre-pignon-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141  
papers

21,851  
citations

56  
h-index

147  
g-index

147  
ext. papers

25,144  
ext. citations

8.4  
avg, IF

6.04  
L-index

#	Paper	IF	Citations
141	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients.. <i>Clinical and Translational Radiation Oncology</i> , <b>2022</b> , 32, 59-68	4.6	2
140	ANTIANGIOGENIC Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.. <i>European Journal of Cancer</i> , <b>2022</b> , 166, 112-125	7.5	0
139	A frequentist one-step model for a simple network meta-analysis of time-to-event data in presence of an effect modifier. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259121	3.7	0
138	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. <i>European Journal of Cancer</i> , <b>2021</b> , 145, 221-229	7.5	14
137	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 156, 281-293	5.3	34
136	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. <i>Lancet Oncology</i> , <b>2021</b> , 22, 727-736	21.7	10
135	Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 158, 40-47	5.3	4
134	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. <i>European Journal of Cancer</i> , <b>2021</b> , 157, 278-290	7.5	2
133	Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6523-6523	2.2	7
132	Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. <i>JAMA Oncology</i> , <b>2020</b> , 6, 206-216	13.4	10
131	Response to R. Jayaraj. <i>Oral Oncology</i> , <b>2020</b> , 102, 104439	4.4	
130	Predictive classifier for intensive treatment of head and neck cancer. <i>Cancer</i> , <b>2020</b> , 126, 5263-5273	6.4	3
129	Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 89-98	7.5	5
128	Are Individual patient data meta-analyses still needed today in oncology? A discussion focused on Head and Neck oncology. <i>Acta Oncologica</i> , <b>2019</b> , 58, 1333-1336	3.2	2
127	Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 222-230	4.9	2
126	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. <i>Oral Oncology</i> , <b>2019</b> , 95, 106-114	4.4	11
125	Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2019</b> , 19, 601-608	2.2	

124	LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 66-73.e6	4.9	14
123	Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 126, 107-115	5.3	77
122	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2995-3006	2.2	120
121	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2018</b> , 7, 416-427	4.4	6
120	Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology. <i>Computational and Mathematical Methods in Medicine</i> , <b>2018</b> , 2018, 1672176	2.8	5
119	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	31
118	Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2018-2027	2.2	61
117	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1221-1237	21.7	156
116	Extrapolation of Survival Curves from Cancer Trials Using External Information. <i>Medical Decision Making</i> , <b>2017</b> , 37, 353-366	2.5	25
115	A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 15924-15933 <sup>11</sup>	2.3	11
114	Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. <i>Oncotarget</i> , <b>2017</b> , 8, 25189-25199	3.3	5
113	Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1818-28	10.3	60
112	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 850-61	8.9	57
111	Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. <i>BMC Medical Research Methodology</i> , <b>2016</b> , 16, 37	4.7	20
110	Comment on "Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis", published in Eur J Cancer 51 (2015), 1570-1579. <i>European Journal of Cancer</i> , <b>2016</b> , 56, 183-185	7.5	5
109	Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150032	3.7	7
108	Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial. <i>Biometrics</i> , <b>2016</b> , 72, 907-16	1.8	21
107	How individual participant data meta-analyses have influenced trial design, conduct, and analysis. <i>Journal of Clinical Epidemiology</i> , <b>2015</b> , 68, 1325-35	5.7	50

106	Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3439-46	2.2	160
105	Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 166-76	7.5	76
104	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 123, 307-14	4.8	13
103	A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer. <i>Statistical Methods in Medical Research</i> , <b>2015</b> , 24, 711-29	2.3	28
102	Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies. <i>Hematology/Oncology Clinics of North America</i> , <b>2015</b> , 29, 1107-22	3.1	35
101	Reply to D. Tural et al. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 259-60	2.2	
100	Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1031-9	2.2	164
99	Preoperative chemotherapy for non-small-cell lung cancer--authorsPreply. <i>Lancet, The</i> , <b>2014</b> , 384, 233	4.0	2
98	A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms. <i>Journal of Molecular Diagnostics</i> , <b>2014</b> , 16, 45-55	5.1	27
97	Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 950-5	3.3	3
96	Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 819-28	21.7	283
95	Reply to Interpretation of concordance measures for clustered data? <i>Statistics in Medicine</i> , <b>2014</b> , 33, 717-8	2.3	
94	Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 1565-77	7.5	119
93	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patientsPdata. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 619-26	21.7	141
92	Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1600-7	9.7	102
91	Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2854-60	2.2	187
90	Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA. <i>Lung Cancer</i> , <b>2013</b> , 82, 149-55	5.9	7
89	ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1101-10	59.2	284

88	Concordance measures in shared frailty models: application to clustered data in cancer prognosis. <i>Statistics in Medicine</i> , <b>2013</b> , 32, 4803-20	2.3	7
87	Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. <i>BMJ Open</i> , <b>2013</b> , 3,	3	34
86	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2173-81	2.2	214
85	Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 1295-307	8.9	11
84	Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1490-502	8.9	65
83	Chemotherapy for colorectal cancer [AuthorsPreply. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, e4	21.7	
82	Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2788-97	2.2	185
81	Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2012</b> , 76, 78-83	5.9	26
80	Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. <i>Oncologist</i> , <b>2012</b> , 17, 1063-72	5.7	80
79	Evaluation of heart murmurs in chinchillas ( <i>Chinchilla lanigera</i> ): 59 cases (1996-2009). <i>Journal of the American Veterinary Medical Association</i> , <b>2012</b> , 241, 1344-7	1	14
78	A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 963-72	8.9	25
77	ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 69-78	5.8	47
76	Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study. <i>Contemporary Clinical Trials</i> , <b>2011</b> , 32, 16-24	2.3	30
75	Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 1032-44	21.7	113
74	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 100, 33-40	5.3	422
73	Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trialB pre-planned analysis and case report of a 5.5-year disease-free survival. <i>Radiation Oncology</i> , <b>2011</b> , 6, 124	4.2	7
72	Reply to S.D. Richman et al. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e356-e357	2.2	1
71	Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1715-21	2.2	1271

70	Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 303, 1729-37	27.4	586
69	MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. <i>Cancer Research</i> , <b>2010</b> , 70, 8288-98	10.1	108
68	Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2181-90	2.2	1176
67	Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 35-42	2.2	283
66	Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2556-64 <sup>2</sup>	2.2	127
65	The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. <i>Supportive Care in Cancer</i> , <b>2009</b> , 17, 1255-61	3.9	15
64	Role of meta-analyses and of large randomized trials in the study of cancer treatments. <i>Lung Cancer</i> , <b>2009</b> , 65, 9-12	5.9	7
63	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. <i>Radiotherapy and Oncology</i> , <b>2009</b> , 92, 4-14	5.3	2127
62	Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. <i>Lancet Oncology</i> , <b>2009</b> , 10, 341-50	21.7	118
61	Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 1504-10	8.9	11
60	Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3552-9	2.2	1492
59	Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3573-81	2.2	149
58	Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, S112-4	4	209
57	Progression-free survival is a surrogate for survival in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5218-24	2.2	278
56	Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3892-8	12.9	63
55	Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, e10-1	2.2	47
54	Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2735-40	2.2	85
53	Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. <i>Cochrane Database of Systematic Reviews</i> , <b>2007</b> , CD004569		26



52	Individual patients data meta-analyses in head and neck cancer. <i>Current Opinion in Oncology</i> , <b>2007</b> , 19, 188-94	4.2	88
51	Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , <b>2007</b> , 8, 994-1000	21.7	86
50	C3-05: Chemotherapy (CT) in addition to surgery or surgery plus radiotherapy (RT) in non-small cell lung cancer (NSCLC): Two meta-analyses using individual patient data (IPD) from randomised controlled trials (RCTs). <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S366-S367	8.9	2
49	Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. <i>Lancet</i> , <b>2006</b> , 368, 843-54	40	822
48	Altered fractionated radiotherapy in head and neck cancer [Authors Preply]. <i>Lancet</i> , <b>2006</b> , 368, 1868	40	1
47	DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 983-91	59.2	1424
46	Comment on "Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature" by T. Berghmans, M. Paesmans, A.P. Meert, C. Mascaux, P. Lothaire, J.J. Lafitte, et al. [Lung Cancer 49 (2005) 13-23.]. <i>Lung Cancer</i> , <b>2006</b> , 51, 261-2; author reply 263-5	5.9	4
45	Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial. <i>Oncology</i> , <b>2006</b> , 71, 40-8	3.6	3
44	Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 64, 47-56	4	494
43	In reply to Drs. Huncharek and Kupelnick. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 65, 958-959	4	4
42	Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 5017s-5021s	12.9	33
41	Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer?. <i>Lancet Oncology</i> , <b>2005</b> , 6, 182-4	21.7	14
40	Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. <i>Annals of Surgical Oncology</i> , <b>2005</b> , 12, 900-9	3.1	204
39	Letter to the editor. <i>Lung Cancer</i> , <b>2005</b> , 48, 149-50	5.9	4
38	Clinical research infrastructures and networks in France: report on the French ECRIN workshop. <i>Thérapie</i> , <b>2005</b> , 60, 183-99	3.8	8
37	Chemotherapy in non-small cell lung cancer: an update of an individual patient data-based meta-analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2005</b> , 129, 1205; author reply 1205-6	1.5	15
36	Quality of life of patients operated on for low rectal cancer: impact of the type of surgery and patients characteristics. <i>Diseases of the Colon and Rectum</i> , <b>2005</b> , 48, 2180-91	3.1	90
35	Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3086-93	2.2	54

34	Chemotherapy in non-small-cell lung cancer: an update of an individual patient data meta-analysis. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 924-5; author reply 925-6	2.2	11
33	Meta-analysis when only the median survival times are known: a comparison with individual patient data results. <i>International Journal of Technology Assessment in Health Care</i> , <b>2005</b> , 21, 119-25	1.8	106
32	Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 351-60	59.2	1781
31	Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 470-84	27.4	260
30	Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. <i>Annals of Surgical Oncology</i> , <b>2004</b> , 11, 274-80	3.1	137
29	Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. <i>Anti-Cancer Drugs</i> , <b>2004</b> , 15, 331-40	2.4	56
28	Resected non-small cell lung cancer: need for adjuvant lymph node treatment? From hope to reality. <i>Lung Cancer</i> , <b>2003</b> , 42 Suppl 1, S57-64	5.9	7
27	Of scientific physicians and objective knowledge. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 52, 1140-1; author reply 1141-2	4	1
26	A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. <i>Statistics in Medicine</i> , <b>2002</b> , 21, 2641-52	2.3	215
25	Initial chemotherapeutic doses and long-term survival in limited small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 1281-2	59.2	21
24	Meta-analyses of randomised clinical trials in oncology. <i>Lancet Oncology, The</i> , <b>2001</b> , 2, 475-82	21.7	72
23	Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 2981-9	2.2	407
22	Is meta-analysis a metaphysical or a scientific method?. <i>Chest</i> , <b>2000</b> , 118, 832-4	5.3	3
21	Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: what you don't see you can't get!. <i>Biometrics</i> , <b>2000</b> , 56, 886-92	1.8	25
20	Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. <i>New England Journal of Medicine</i> , <b>1999</b> , 341, 476-84	59.2	1266
19	Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. <i>Cancer</i> , <b>1998</b> , 82, 1049-55	6.4	52
18	Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. <i>Journal of Surgical Oncology</i> , <b>1998</b> , 69, 88-93	2.8	104
17	Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. <i>Journal of Hepatology</i> , <b>1998</b> , 29, 129-34	13.4	331



16	Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases <b>1998</b> , 69, 88		3
15	Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis. <i>Cancer</i> , <b>1996</b> , 77, 2413-4	6.4	32
14	The role of chest irradiation in small cell lung cancer. <i>Cancer Treatment and Research</i> , <b>1995</b> , 72, 255-71	3.5	
13	Triangular test and randomized trials: practical problems in a small cell lung cancer trial. <i>Statistics in Medicine</i> , <b>1994</b> , 13, 1415-21	2.3	6
12	Proposal for a new section in Lung Cancer on ongoing randomized trials. <i>Lung Cancer</i> , <b>1994</b> , 11, 401-3	5.9	
11	Meta-analyses of randomized clinical trials: how to improve their quality?. <i>Lung Cancer</i> , <b>1994</b> , 10 Suppl 1, S135-41	5.9	3
10	Early stopping rules and long-term follow-up in phase III trials. <i>Lung Cancer</i> , <b>1994</b> , 10 Suppl 1, S151-9	5.9	6
9	Controversies in the management of small cell lung cancer: thoracic radiotherapy in limited disease. <i>Lung Cancer</i> , <b>1993</b> , 9, 253-263	5.9	2
8	Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 1848-52	59.2	221
7	A meta-analysis of thoracic radiotherapy for small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1618-24	59.2	1017
6	ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Fédération Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. <i>International Journal of</i>	4	231
5	Gender differences in the response of hepatic fatty acids and cytosolic fatty acid-binding capacity to alcohol consumption in rats. <i>Experimental Biology and Medicine</i> , <b>1991</b> , 198, 584-90	3.7	22
4	Apolipoprotein AI is a serum and tissue marker of liver fibrosis in alcoholic patients. <i>Alcoholism: Clinical and Experimental Research</i> , <b>1989</b> , 13, 829-33	3.7	21
3	Fatty acid-binding protein: a major contributor to the ethanol-induced increase in liver cytosolic proteins in the rat. <i>Hepatology</i> , <b>1987</b> , 7, 865-71	11.2	69
2	Apolipoprotein AI and alcoholic liver disease. <i>Hepatology</i> , <b>1986</b> , 6, 1391-5	11.2	37
1	Prognostic value of serum fibronectin concentration in alcoholic cirrhotic patients. <i>Hepatology</i> , <b>1985</b> , 5, 819-23	11.2	29